Quantcast
Home > Quotes > CTIC
CTIC

CTI BioPharma Corp. (DE) Common Stock (CTIC) Quote & Summary Data

$1.48
*  
0.03
1.99%
Get CTIC Alerts
*Delayed - data as of Dec. 10, 2018  -  Find a broker to begin trading CTIC now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CTIC Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6
Today's High / Low
$ 1.54 / $ 1.48
Share Volume
90,231
50 Day Avg. Daily Volume
191,980
Previous Close
$ 1.51
52 Week High / Low
$ 5.3601 / $ 1.50
Market Cap
85,823,072
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.5

Intraday Chart

Shares Traded

Share Volume:
90,231
50 Day Avg. Daily Volume:
191,980

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.87

Trading Range

The current last sale of $1.48 is -1.33% Lower than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.54 $ 5.3601
 Low: $ 1.48 $ 1.50

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partner, Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, has commercialization rights outside the United States, or the U.S. PIXUVRI PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties.  ... More ...  


Risk Grade

Where does CTIC fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.51
Open Date:
Dec. 10, 2018
Close Price:
$ 1.48
Close Date:
Dec. 10, 2018

Consensus Recommendation

Analyst Info